Category: CLTI

VSGBI President’s Symposium spotlights data-driven financial incentives for PAD revascularisation

The President’s Symposium at the Vascular Society of Great Britain and Ireland (VSGBI) annual scientific meeting (23–25 November, Brighton, UK) featured Rob Sayers’ (University of Leicester, UK) presentation titled ‘CLTI CQUIN has raised the profile of PAD and will lead to fewer amputations’. Sayers’ take-home message for delegates was that the National Health Service (NHS)’s […]

The post VSGBI President’s Symposium spotlights data-driven financial incentives for PAD revascularisation appeared first on Vascular News.

SWING trial 12-month data: Novel sirolimus DCB shows “great promise” in “challenging” CLTI population

The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI [chronic limb-threatening ischaemia] population,” and has a primary patency rate of 80% at 12 months in a per-protocol analysis population. Ramon Varcoe (Prince of Wales Hospital, Sydney, Australia) presented these findings from the SWING first-in-human study at […]

The post SWING trial 12-month data: Novel sirolimus DCB shows “great promise” in “challenging” CLTI population appeared first on Vascular News.

Physicians call for clinical application of “helpful, meaningful” AMPREDICT decision support tool

Researchers have found that the AMPREDICT decision support tool (DST) demonstrates “strong usability characteristics and clinical relevance” in amputation level decision-making for patients with chronic limb-threatening ischaemia (CLTI). Daniel C Norvell (VA Puget Sound Health Care System, Seattle, USA) and colleagues suggest in an online European Journal of Vascular and Endovascular Surgery (EJVES) article that, […]

The post Physicians call for clinical application of “helpful, meaningful” AMPREDICT decision support tool appeared first on Vascular News.